Press Release : Pfizer and BioNTech Receive First -3-

COVID-19 vaccine (including a potential second booster dose of BNT162b2 
and/or a potential booster dose of a variation of BNT162b2 having a 
modified mRNA sequence); the potential of BNT162b2 for adolescents 12 to 
15 years of age, evaluation of BNT162b2 in children 6 months to 11 years 
old, anticipated timing of regulatory submissions, regulatory approvals 
or authorizations and anticipated manufacturing, distribution and 
supply); our expectations regarding the potential characteristics of 
BNT162b2 in our clinical trials and/or in commercial use based on data 
observations to date; the ability of BNT162b2 to prevent COVID-19 caused 
by emerging virus variants; the expected time point for additional 
readouts on efficacy data of BNT162b2 in our clinical trials; the nature 
of the clinical data, which is subject to ongoing peer review, 
regulatory review and market interpretation; the timing for submission 
of data for, or receipt of, any marketing approval or Emergency Use 
Authorization; our contemplated shipping and storage plan, including our 
estimated product shelf life at various temperatures; the risk that 
demand for any products may be reduced or no longer exist; the ability 
of BioNTech to supply the quantities of BNT162 to support clinical 
development and market demand, including our production estimates for 
2021; and challenges related to public vaccine confidence or awareness. 
Any forward-looking statements in this press release are based on 
BioNTech's current expectations and beliefs of future events, and are 
subject to a number of risks and uncertainties that could cause actual 
results to differ materially and adversely from those set forth in or 
implied by such forward-looking statements. These risks and 
uncertainties include, but are not limited to: the ability to meet the 
pre-defined endpoints in clinical trials; competition to create a 
vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Annual Report on Form 20-F for the Year Ended December 31, 
2020, filed with the SEC on March 30, 2021, which is available on the 
SEC's website at www.sec.gov. All information in this press release is 
as of the date of the release, and BioNTech undertakes no duty to update 
this information unless required by law. 
 
   Pfizer Contacts: 
 
   Media Relations 
 
   Amy Rose 
 
   [phone] 
 
   https://www.globenewswire.com/Tracker?data=nhK6gvRQOzjXOgEQZIi3yapIYXUmeBX_MxW09juPMv_um4sQcRir34MJKYj-YJNA-ECbu19VOgeDh0eULWQL-rcUVSWrVG1IVd03umpZ9e0= 
[e-mail] 
 
   Investor Relations 
 
   Chuck Triano 
 
   [phone] 
 
   https://www.globenewswire.com/Tracker?data=rSwPClkDa-kJq1itsw63yge6XOVhIfyu2F-ABOTbTDq_cvtEHVU-HUmBuaNl0V1Y_w2mvEET0Q2lhSuytSdl_wyWJ6WjPG0t6uKP65IjXMd4emIqy-vNEawoDhU8daEU 
[e-mail] 
 
   BioNTech Contacts: 
 
   Media Relations 
 
   Jasmina Alatovic 
 
   [phone] 
 
   https://www.globenewswire.com/Tracker?data=ARph87GRpeEwT6jT7b3E09zXyM91uHAm3mSJvXFTD2mB7I9rZVjq0HqUQlUiS6ooB6Cj01qhjHToBRVJX3-gNglCm8bixAPXXgGtb9QGt10= 
[e-mail] 
 
   Investor Relations 
 
   Sylke Maas, Ph.D. 
 
   [phone] 
 
   https://www.globenewswire.com/Tracker?data=Uyv5z556CMI24YX_NjuJSPcZUz0NCOPBdse_h5-amSnQLIpsXZDjEeHEeFiUP9QMztPo_9u7zJhX0yspnLYhfh1Bh6CAHDYJGgL639bp75g= 
[e-mail] 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 11, 2021 02:30 ET (06:30 GMT)